 A message from Sideways Frequency |
|
Bio Stem Technologies Accelerates Into 2026 With Transformative Acquisition, Seven Straight Profitable Quarters, and Entry into Advanced and Acute Wound Care Markets! BioStem Technologies (OTCQB: BSEM) is emerging as one of the most compelling small-cap MedTech companies as 2026 begins. The company just completed the acquisition of BioTissue Holdings' surgical and wound care business, instantly expanding its footprint into hospital-based, acute, and surgical wound care. With established product lines like Neox® and Clarix®, a nationwide sales force, and key GPO contracts, BioStem is now positioned to capture a $300–$350 million addressable market, spanning chronic and acute wound care, burns, and soft-tissue repair. Zacks Small Cap Research has assigned BSEM a $25.50 price target, highlighting confidence in the company's profitable growth, clinical validation, and expanding market presence. Coupled with seven consecutive profitable quarters, strong gross margins of 88.5%, and $16 million in cash post-acquisition, BSEM is demonstrating operational excellence rarely seen in small-cap regenerative medicine. Backed by clinically validated BioREtain® technology, FDA-level studies, and a potential Nasdaq uplisting in mid-2026, BSEM is gaining traction with both institutional investors and healthcare providers. Discover why BSEM is setting the standard for profitable, clinically proven MedTech growth in 2026.
|
| This message is a paid advertisement for BioStem Technologies (OTCQB: BSEM) from Sideways Frequency. Schaeffer's Investment Research Inc. receives a fixed fee for each subscriber that clicks on a link in this email. Other than the compensation received for this advertisement sent to subscribers, Schaeffer's Investment Research Inc. and its principals are not affiliated with BioStem Technologies (OTCQB: BSEM). Schaeffer's Investment Research Inc. and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Schaeffer's Investment Research Inc. nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Schaeffer's Investment Research Inc. to buy or sell any security. Schaeffer's Investment Research Inc. has not evaluated the accuracy of any claims made in this advertisement. Schaeffer's Investment Research Inc. recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies (OTCQB: BSEM) on BioStem Technologies (OTCQB: BSEM) website for additional information. To stop receiving these emails, unsubscribe. |
Post a Comment
Post a Comment